March 2018 VERSION 2.2. TB/HIV Indicators

Similar documents
Monitoring, Evaluation, and Reporting (MER) Guidance (v.2.3): TB and HIV

Monitoring, Evaluation, and Reporting (MER 2.0) Indicator Reference Guide

DATIM Analytics Improvements. Webinar Series 1 Thursday, March 2, 2017

PEPFAR Expenditure Analysis Cheat Sheet PEPFAR Applied Learning Summit

Monitoring, Evaluation, and Reporting (MER) Guidance (v2.3): PMTCT. Presenter: Jenny Albertini, S/GAC Date: October 2018

PERFORMANCE INDICATOR REFERENCE SHEETS FOR KEY POPULATIONS

PEPFAR/MoH Data Alignment. Webinar 3 June 20, 2018

PEPFAR MER 2.0 Reference App for South Africa. 1. Goals/Scope. 2. Background

Monitoring, Evaluation, and Reporting (MER) Guidance (v.2.3): Orphans and Vulnerable Children (OVC)

PEPFAR 3.0 Controlling the epidemic & delivering on the

Day 2 MER Analytics Exercise PMTCT Data Analysis

2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE

Monitoring, Evaluation, and Reporting (MER) Guidance (v.2.3): LABORATORY. Presenter(s): Peter Minchella, PhD Date: August 2018

UGANDA NATIONAL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME

PEPFAR-to-MoH Data Alignment An overview. Webinar One July 20, 2017

Current status of implementation and monitoring and evaluation of collaborative TB/HIV activities. Avinash Kanchar

Assessing the programmatic management of drug-resistant TB

HIV Clinicians Society Conference TB/HIV Treatment Cascade

ANALYSIS AND USE OF HEALTH FACILITY DATA. Guidance for tuberculosis programme managers

Ministry of Health. National Tuberculosis Control Program INTEGRATED TB HIV PROGRAM REPORT (JANUARY JUNE 2015)

Session-1: Template for country presentation (EXISTING Indicators)

Definitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013

From to zero new infections, zero deaths, reduced stigma

IPT IMPLEMENTATION- SWAZILAND EXPERIENCE

Integrated VL/EID& TB Data Review Meeting 23/3/2018 PIATO

Tuberculosis: Opportunities and Challenges for Achieving HIV Epidemic Control

ADX-HIV content schema. Leveraging a standards-based aggregate data exchange schema to operationalize HIV indicator reporting

Intensified TB Case Finding using a TB screening tool integrated into an HIV clinical record: Experiences from the Eastern Cape Province

No. individuals current on treatment (ART) - PEPFAR Indicator Reference Sheets

Christian Gunneberg MO WHO The 14th Core Group Meeting of the TB/HIV Working Group November 11-12, 2008, Addis Ababa, Ethiopia

World Health Organization HIV/TB Facts 2011

Investing for Impact

NAME OF HEALTH UNIT NAME OF SUB-DISTRICT NAME OF DISTRICT

ESSENTIAL PACKAGE FOR HIV CARE AND TREATMENT. Essential Package for HIV Care and Treatment

OVC_HIVSTAT FAQ Q1. Do partners need to report results for OVC_HIVSTAT in FY17 at Q2 and Q4?

ANALYSIS AND USE OF HEALTH FACILITY DATA: Guidance for HIV programme managers WORKING DOCUMENT, JUNE 2018

Scaling up collaborative TB/HIV activities: achievements, challenges, and opportunities in Viet Nam

ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM

IPT Policy Review South Africa. WHO TB/HIV Working Group meeting

INNOVATIONS. The Passing of a Pioneer. Remembering Dr. Mathilde Krim

PROGRESS ON IMPLEMENTATION OF THE 3Is IN SOUTH AFRICA. Yogan Pillay Deputy Director General Strategic Health Programmes South Africa

: uptake and impact of Xpert MTB/RIF

Achieving the 3 rd 90 in PEPFAR-supported countries:

The first National TB Prevalence Survey Rwanda 2012

TB prevention studies in PLHIV: recent updates and what can they tell us for the future?

Situation of the HIV Epidemic in Cambodia

The CQUIN Learning Network

Annex 13. Indicators for HIV testing services reference sheet

OPTIONS REVIEW AND DOCUMENTATION OF M&E INDICATORS FOR ORAL PrEP

End TB Strategy top 10 indicators: current status in participant countries

SURVEY FINDINGS April 28, 2017

REVISED UPHOLD PERFORMANCE MONITORING PLAN Oct 12 th May

Tuberculosis prevention: An under prioritized YET critical intervention to reduce child tuberculosis morbidity and mortality

The 1 st National TB Prevalence Survey Nigeria 2012

Bukoba Combination Prevention Evaluation: Effective Approaches to Linking People Living with HIV to Care and Treatment Services in Tanzania

Analysis of the epidemiological impact of tuberculosis in the Republic of Moldova

Organizational HIV Treatment Cascade Guidance for Construction. Introduction. Background

The Nexus Between 90/90/90 and Epidemic Control. Ambassador Deborah Birx IAS July 2018

Cost-effectiveness of ART and the Three I s for HIV/TB to prevent tuberculosis

The President s Emergency Plan for AIDS Relief Next Generation Indicators

GLOBAL AIDS MONITORING REPORT

INH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific

TB Control activities and Success factors and Challenges for monitoring and Evaluation of the Mangement of LTBI in Cambodia

Supplementary appendix

Treating HIV and TB: New evidence, Challenges & Prospects

Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation

Xpert MTB/RIF test Rollout and Implementation Plan

PEPFAR and Treatment 2.0

MODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit

What is new in WHO-guidelines relevant for childhood TB?

My heart is racing. Managing Complex Cases. Case 1. Case 1

TB Control in Namibia : Progress and Technical Assistance

LEPROSY AND HIV CO-INFECTION

IPT BOTSWANA EXPERIENCE

PERSON CENTRED HIV PATIENT MONITORING AND CASE SURVEILLANCE

Tuberculosis Screening and IPT: Experience from India

Eswatini NTCP and Baylor Global TB Pilot Project on DR-TB Contact Management. WHO Child and Adolescent Working Group October 2018 Dr Debrah Vambe

The President s Emergency Plan for AIDS Relief: Indicators, Reporting Requirements, and Guidelines for Focus Countries. Revised for FY2006 Reporting

Call for Expression of Interest (EOI) Grant to Implement HIV Prevention, Care and Treatment Activities for Men who have Sex with Men in South Africa

Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite

SA TB Guidelines The interface with Advanced Clinical Care

Billing Code: P DEPARTMENT OF HEALTH AND HUMAN SERVICES. Centers for Disease Control and Prevention. [30Day-18-17AUZ]

Patients at High Risk Experience, Guidelines, and Best Practices. Mozambique. José Tique, MD MPH MoH July 17-19, 2017 Harare, Zimbabwe

Time to implement: WHO guidelines on TB Preventive Treatment

World Health Organization Strategy for HIV Drug Resistance Surveillance in Low- and Middle- Income Countries

The Lancet Infectious Diseases

Comparative evaluation of diagnostic performance of Xpert between paired IS and GW in children <3.5 years in Cape Town, SA

The New WHO guidelines on intensified TB case finding and Isoniazid preventive therapy and operational considerations

Mozambique Draft 3Is workplan

Global Perspectives on Treat All for Children and Adolescents with HIV. PATA Global Summit Shaffiq Essajee

Principle of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos

Differentiated Care Improving Engagement and Retention in HIV Care. Meg Doherty, MD PhD MPH World Health Organization

Costing of the Sierra Leone National Strategic Plan for TB

Response to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria.

Assessment of the performance of TB surveillance in Kenya main findings, key recommendations and associated investment plan

TB FIT Modelling. 24th Annual PhilCAT Convention. Ivor Langley and Ewan Tomeny Liverpool School of Tropical Medicine AUGUST 2017

TB: A Supplement to GP CLINICS

Latent TB Infection in the WHO European Region and recommendations on LTBI s M&E framework

Xpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection. Results of Group Work

TB/HIV management survey

Transcription:

March 2018 VERSION 2.2 TB/HIV Indicators

PEPFAR MER 2.0 V.2 Indicators: Emphasis on Interventions to End HIV Epidemic and more aligned to the 95:95:95 goals 2

3

MER INDICATOR GROUPINGS Prevention MER 2.0: Frequency of Reporting Table 90: Knowing your HIV Status 90-90: On ART 90-90-90: Viral Suppression Health Systems PREP_NEW HTS_TST* TX_NEW TX_RET SC_STOCK VMMC_CIRC PMTCT_STAT* TX_CURR TX_PLVS HRH_PRE KP_PREV PMTCT_HEI* PMTCT_ART HRH_CURR PP_PREV TB_STAT* TB_ART HRH_STAFF TB_PREV OVC_HIVSTAT TX_TB EMR_SITE OVC_SERV PMTCT_FO LAB_PTCQI KP_MAT GENDER_GBV FPINT_SITE * Includes Positive disaggregate (POS) Quarterly Semiannual Annual Report 3 months of Results for these indicators at each reporting cycle Q1, Q2, Q3, Q4 Report 6 months for theses indicators at each reporting cycle Q2 and Q4 Report results for the entire 12 month reporting period for these indicators at the Q4 reporting cycle

TB/HIV Indicators TB_PREV TB_STAT TB_ART TX_TB

Prevention Indicators PREP_NEW VMMC_CIRC KP_PREV PP_PREV TB_PREV KP_MAT GEND_GBV OVC_SERV FP_SITE 1. PREP_NEW 2. VMMC_CIRC 3. KP_PREV 4. PP_PREV 5. TB_PREV 6. OVC_SERV 7. GEND_GBV 8. FPINT_SITE 9. (KP_MAT*)

Prevention: TB_PREV (Indicator reported biannually or Semi-annually to OGAC/Uganda we report quarterly) Indicator Code: TB_PREV NEW Indicator Definition: Numerator: Denominator Proportion of ART patients who completed a standard course of TB preventive therapy within the reporting period Number of ART patients who completed a course of TB preventive therapy during the reporting period (for continuous IPT programs, this includes the patients who have completed the first 6 months of isoniazid preventive therapy (IPT)) Number of ART patients who are expected to complete a course of TB preventive therapy during the reporting period (for programs using continuous IPT, this includes only the patients who are scheduled to complete the first 6 months of therapy)

Prevention: TB_PREV (Disaggregates) (Indicator reported biannually or Semi-annually to OGAC/Uganda we report quarterly) Disaggregation Details both for Numerator & Denominator Type of TB Preventative Therapy (TPT) by ART Start: IPT by newly enrolled on ART IPT by previously enrolled on ART Alternative TPT regimen by newly enrolled on ART Alternative TPT regiment by previously enrolled on ART Age/Sex: <15 Female, 15+ Female, <15 Male, 15+ Male Data Source IPs Submission in HIBRID Start of Therapy: Denominator Disaggregates only Started during this reporting period Started in last reporting period Updated disaggregation titled, Type of TB Preventative Therapy (TPT) by ART Start

90: Knowing your HIV Status HTS_TST PMTCT_STAT PMTCT_EID TB_STAT OVC_HIVSTAT (New!) PMTCT_FO 1. HTS_TST 2. PMTCT_STAT 3. PMTCT_EID 4. PMTCT_HEI_POS 5. PMTCT_FO 7. OVC_HIVSTAT 6. TB_STAT 8. HTS_SELF

Knowing your HIV Status: TB_STAT (includes TB_STAT_POS) (Indicator reported biannually or Semi-annually to OGAC/Uganda Reports quarterly) Indicator Code: TB_STAT (includes TB_STAT_POS) Indicator Definition: Percentage of new and relapsed TB cases with documented HIV status Numerator: Number of new and relapsed TB cases with documented HIV status, during the reporting period Denominator: Total number of new and relapsed TB cases, during the reporting period

Knowing your HIV Status: TB_STAT (includes TB_STAT_POS) (Disaggregates) (Indicator reported biannually or Semi-annually to OGAC/Uganda we report quarterly) Disaggregation - Details Data Source Numerator Disaggregates: Age/Sex (Coarse Disaggregate) <15 M, 15+ M, <15 F, 15+ F Results: Known HIV-positive at service entry; Newly tested HIV-positive; Tested HIV- negative Age/Sex/Result (Coarse Disaggregate): <15 M Known HIV-Positive at service entry, <15 M Newly tested HIV-Positive, <15 F Known HIV-Positive at service entry, <15 F Newly tested HIV-Positive, 15+ M Known HIV-Positive at service entry, 15+ M Newly Tested HIV-Positive, 15+ F Known HIV-Positive at service entry, 15+ F Newly Tested HIV-Positive, <15 M Negative, <15 F Negative, 15+ M Negative, 15+ F Negative Denominator Disaggregates: Age/Sex (Coarse Disaggregate) <15 M, 15+ M, <15 F, 15+ F DHIS2 HMIS 106a: Health Unit Quarterly Report Tuberculosis/leprosy Services Section #3.1 Tables a & c IPs Submission in HIBRID

90-90: On ART TX_NEW TX_CURR TB_ART TX_TB (New!) PMTCT_ART 1.TX_NEW 2. TX_CURR 3. PMTCT_ART 4. TB_ART 5. TX_TB

ON ART: TB_ART (Indicator reported biannually or Semi-annually to OGAC/Uganda we report quarterly) Indicator Code: Indicator Definition: TB_ART The number of HIV-positive new and relapsed TB cases on ART during TB treatment Numerator: Number of TB cases with documented HIV-positive status who start or continue ART during the reporting period Denominator: N/A

ON ART: TB_ART (Disaggregates) (Indicator reported biannually or Semi-annually to OGAC/Uganda we report quarterly) Disaggregation - Details Data Source Numerator Disaggregates Age/Sex: (Finer Disaggregates) <1, 1-9, 10-14 M, 10-14 F, 15-19 M, 15-19 F, 20-24 M, 20-24 F, 25-29 M, 25-29 F, 30-34 M, 30-34 F, 35-39 M, 35-39 F, 40-49 M, 40-49 F, 50+ M, 50+ F Age/Sex: (Coarse Disaggregates) <1, <15 M, <15 F, 15+ M, 15+ F DHIS2 HMIS 106a: Health Unit Quarterly Report Tuberculosis/leprosy Services Section: #3.1 Tables a & c IPs Submission in HIBRID Current/New on ART: Currently on ART; New on ART Denominator Disaggregate N/A

ON ART: TX_TB (Indicator reported biannually or Semi-annually to OGAC/Uganda we report quarterly) Indicator Code: Indicator Definition: TX_TB The proportion of ART patients screened for TB in the semiannual reporting period who are receiving TB treatment. Numerator: The number of ART patients who were started on TB treatment during the semiannual reporting period. Denominator: The number of ART patients who were screened for TB at least once during the semiannual reporting period.

ON ART: TX_TB (Disaggregates) (Indicator reported biannually or Semi-annually to OGAC/Uganda we report quarterly) Disaggregation - Details Numerator Disaggregates Age/Sex: (Finer Disaggregates) <1, 1-9, 10-14 M, 10-14 F, 15-19 M, 15-19 F, 20-24 M, 20-24 F, 25-29 M, 25-29 F, 30-34 M, 30-34 F, 35-39 M, 35-39 F, 40-49 M, 40-49 F, 50+ M, 50+ F Current/New on ART: The number of patients starting TB treatment who newly started ART during the reporting period; The number of patients starting TB treatment who were already on ART prior to the start of the reporting period Age/Sex: (Coarse Disaggregates) <1, <15 M, <15 F, 15+ M, 15+ F Denominator Disaggregate Screen Result: Positive: The number of ART patients who at least one positive screen during the reporting period; The number of ART patients who had all negative screens during the reporting period. Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease [Disaggregate of Specimen Sent] Diagnostic Test: GeneXpert MTB/RIF assay (with or without other testing); Smear microscopy only; Additional test other than GeneXpert Age/Sex (Coarse Disaggregate) <15 F, 15+ F, <15 M, 15+ M Data Source DHIS2 TB Register IPs Submission in HIBRID (To Synchronise with totals from HMIS 106a HIV ART Section: Num: #26 Den: #24)

THANK YOU